IGI Laboratories, Inc. Announces Fourth ANDA Submission of 2015

IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has submitted its fourth abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-six. Jason Grenfell-Gardner, President and CEO of the Company, commented, "Our team continues to execute on the targets we have established for 2015 submissions. We believe our current pipeline of twenty-six submissions, exclusive of our four partnered submissions, pending approval by the FDA now has a combined addressable market of over $841 million based on April 2015 data from IMS Health."